Physician profile
Marc C Hellrung
NPI 1366473464
$14,275.03
in general payments reported to CMS, 2019-2025
42 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,118 · 2020: $1,830 · 2021: $2,070 · 2022: $2,346 · 2023: $2,313 · 2024: $1,824 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,911.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,904.16 | 2019-2025 | |
| Novo Nordisk INC | $1,550.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,374.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,268.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,034.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $978.78 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $672.16 | 2019-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $520.83 | 2022-2025 | |
| Abbott Laboratories | $514.89 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $487.18 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $461.18 | 2019-2025 | Dificid, Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $454.52 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $331.84 | 2019-2022 | |
| Allergan, INC. | $328.09 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $315.56 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Hellrung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.